1-6 of 6
Deborah A. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)

Rakesh Popat, Ajay Nooka, MDMPH, Keith Stockerl-Goldstein, MD, Rafat Abonour, MD, Ryan Ramaekers, MD, Amit Khot, MD, Adam Forbes, MD, Cindy Lee, MD, Bradley Augustson, MBBS FRACP FRCPA, Andrew Spencer, Maria-Victoria Mateos, MD PhD, Bikramjit Chopra, PhD, Rachel Rogers, MS, Deborah A Smith, PharmD, Jacqueline Davidge, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Anne Yeakey, MD, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Hang Quach, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-139332
Published: 2020
Journal Articles

A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)

Christine I Chen, MD, Susi Snitzler, RN, Olga Levina, RN, Tong (Trina) Wang, RN, Lisa W Le, MSc, Harminder Paul, Ellen Nong Wei, Anthea Lau, Michelle Queau, James B Johnston, MD, Suzanne Trudel, MD, Deborah A Smith
Journal: Blood
Blood (2015) 126 (23): 1742.
https://doi.org/10.1182/blood.V126.23.1742.1742
Published: 2015
Journal Articles

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Clinical Trials & Observations
Andrew Spencer, Sung-Soo Yoon, Simon J. Harrison, Shannon R. Morris, Deborah A. Smith, Richard A. Brigandi, Jennifer Gauvin, Rakesh Kumar, Joanna B. Opalinska, Christine Chen
Journal: Blood
Blood (2014) 124 (14): 2190–2195.
https://doi.org/10.1182/blood-2014-03-559963
Published: 2014
Includes: Supplemental data
Journal Articles

Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis

Robert J. Arceci, M.D., Ph.D., Carl E. Allen, MD, PhD, Ira Dunkel, M.D., Eric D. Jacobsen, MD, James Whitlock, Robert Vassallo, M.D., Ivan M. Borrello, MD, Allen Oliff, MD, Shannon R. Morris, MD, PhD, Beth Ann M Reedy, Alison Portnoy, Deborah A. Smith, PharmD, Bob Noble, Amy A. Murnane, Stephen A. Szabo, Carlos Rodriguez-Galindo, Mark L. Heaney, MD, PhD, Kenneth L. McClain, MD, PhD, Sarah Vaseilbuh, MD
Journal: Blood
Blood (2013) 122 (21): 2907.
https://doi.org/10.1182/blood.V122.21.2907.2907
Published: 2013
Journal Articles

An Open-Label Phase 2 Study Of Ofatumumab In Combination With a Novel AKT Inhibitor (Afuresertib) In Previously Treated Patients With Chronic Lymphocytic Leukemia (CLL)

Christine I. Chen, MD, Susi Snitzler, RN, Trina Wang, RN, Harminder Paul, Lisa W Le, Ellen Nong Wei, MSc, Anthea Lau, Deborah A Smith, PharmD, Michelle Brown, James B Johnston, MD, Suzanne Trudel, MD, MSC, FRCPC
Journal: Blood
Blood (2013) 122 (21): 4175.
https://doi.org/10.1182/blood.V122.21.4175.4175
Published: 2013
Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD
Journal: Blood
Blood (2013) 122 (21): 283.
https://doi.org/10.1182/blood.V122.21.283.283
Published: 2013